Gilead Sciences | GILD - PE Price to Earnings

Stock Price
129.58
Daily Change
-2.48 -1.88%
Monthly
-6.47%
Yearly
26.42%
Q2 Forecast
126.98

Gilead Sciences reported 17.7 in PE Price to Earnings for its fiscal quarter ending in March of 2026.





Pe Change Date
AbbVie 23.03 1 Mar/2026
Agios Pharmaceuticals 3.56 0 Mar/2026
ALKERMES 39.33 19.8 Mar/2026
Alnylam Pharmaceuticals 80.04 90.66 Mar/2026
Amgen 19.84 5.47 Mar/2026
Biogen 13.7 0.32 Mar/2026
BioMarin Pharmaceutical 15.28 3.96 Mar/2026
Bristol-Myers Squibb 9.08 0.2 Mar/2026
Eli Lilly 40.27 0.06 Mar/2026
Gilead Sciences 17.7 2.07 Mar/2026
GlaxoSmithKline 14.87 3.72 Mar/2026
Glaxosmithkline 11.66 0.28 Dec/2025
Incyte 15.35 0.51 Mar/2026
J&J 24.53 0.91 Mar/2026
Merck 16.52 2.6 Mar/2026
Moderna 27.22 14.51 Jun/2023
Neurocrine Biosciences 28.09 807.38 Mar/2026
Novartis 20.17 2.32 Mar/2026
Pfizer 9.32 5.16 Mar/2026
PTC Therapeutics 9.98 3.25 Dec/2025
Puma Biotechnology 13.93 44.88 Jun/2024
Regeneron Pharmaceuticals 25.14 7.03 Mar/2026
Sanofi 11.84 0.14 Mar/2026
Sarepta Therapeutics 27.27 0 Dec/2025
United Therapeutics 20.42 3.1 Mar/2026
Vertex Pharmaceuticals 25.82 0.33 Mar/2026